Vanda Pharmaceuticals (VNDA) Change in Accured Expenses (2010 - 2026)

Vanda Pharmaceuticals has reported Change in Accured Expenses for 17 years, with the latest figure at $1.5 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 73.74% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.7 million (up 88.77% YoY) and the FY2025 annual result came in at $15.8 million, up 826.23% from the prior year.
• Change in Accured Expenses declined to $1.5 million in Q1 2026 per VNDA's latest filing, from $9.1 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $13.4 million in Q1 2022 and troughed at -$10.8 million in Q1 2023.
• A 5-year average of $1.2 million and a median of $1.2 million in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses surged 4878.57% in 2022, then sank 2079.74% in 2025.
• Over 5 years, Change in Accured Expenses stood at -$3.3 million in 2022, then soared by 201.65% to $3.3 million in 2023, then sank by 163.85% to -$2.1 million in 2024, then surged by 526.75% to $9.1 million in 2025, then slumped by 83.7% to $1.5 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $1.5 million, $9.1 million, and -$10.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.